Home / Market News / $SLN
benzinga Corporate Catalyst Impact 92/100 ● positive

Silence Therapeutics shares are trading higher after the company announced that it will be acquired by Merck KGaA, Darmstadt, Germany, in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.

Oct 19, 2026, 2:20 PM UTC · Primary ticker $SLN

Silence Therapeutics shares are surging following the announcement of its acquisition by Merck KGaA. This all-cash transaction values Silence Therapeutics at a significant premium, highlighting the strategic importance of its RNAi technology. The deal is a major positive for Silence Therapeutics shareholders and signals potential consolidation in the biotech sector.

This acquisition is a major corporate catalyst, driving Silence Therapeutics shares significantly higher due to the substantial premium offered. For Merck KGaA, it represents a strategic expansion into RNAi therapeutics, potentially strengthening its pipeline and market position. The all-cash nature of the deal reduces integration risk for Silence shareholders. This event could spark further M&A activity in the biotechnology sector, particularly among companies with promising RNAi platforms. Investors in other small to mid-cap biotech firms with innovative technologies might see increased interest, while larger pharmaceutical companies could be on the lookout for similar acquisition targets.

$SLN positive Acquisition target, significant premium
$MRK.DE neutral Acquirer, strategic expansion
$MRK neutral Acquirer (US listing of Merck KGaA)
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.